Physician profile
Iris Lee Lin
NPI 1689165417
$31,853.66
in general payments reported to CMS, 2019-2025
27 companies · $1,989 in 2025
The $1,989 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $9,500 · 2023: $20K · 2024: $553 · 2025: $1,989.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Grant: $20K · Food and Beverage: $2,705 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $23.28.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Grant | $19,625.00 |
| Food and Beverage | $2,705.38 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $23.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $16,625.00 | 2022-2023 | |
| Medtronic, INC. | $7,500.00 | 2023 | Activa PC |
| Boston Scientific Corporation | $5,000.00 | 2023 | Vercise |
| Abbvie INC. | $685.06 | 2025 | |
| Amneal Pharmaceuticals LLC | $440.60 | 2024-2025 | Crexont, Ongentys 50mg Capsules 30 |
| Neurocrine Biosciences, INC. | $299.21 | 2024-2025 | Ingrezza |
| Mdd US Operations, LLC | $178.52 | 2025 | Gocovri, Apokyn |
| Acadia Pharmaceuticals INC | $173.34 | 2024-2025 | Nuplazid |
| Teva Pharmaceuticals USA, INC. | $155.50 | 2023-2025 | Austedo Xr, Austedo Xr |
| Biogen, INC. | $145.38 | 2024-2025 | Vumerity |
| Novartis Pharmaceuticals Corporation | $93.75 | 2024-2025 | |
| Lilly USA, LLC | $88.41 | 2024-2025 | Amyvid, Kisunla, Emgality |
| Pfizer INC. | $70.72 | 2024-2025 | |
| Argenx US, INC. | $53.94 | 2025 | Vyvgart Hytrulo, Vyvgart |
| Ipsen Biopharmaceuticals, INC | $48.51 | 2023 | Dysport |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merz Pharmaceuticals, LLC | $41.28 | 2025 | Xeomin |
| Lundbeck LLC | $29.20 | 2025 | Vyepti |
| Revance Therapeutics, INC. | $27.40 | 2025 | Daxxify |
| Kyowa Kirin, INC. | $25.34 | 2023 | Nourianz |
| Sk Life Science, INC. | $24.35 | 2025 | |
| Monteris Medical Corporation | $24.01 | 2025 | Neuroblate |
| Genentech USA, INC. | $23.03 | 2025 | Ocrevus Zunovo |
| Jazz Pharmaceuticals INC. | $22.29 | 2025 | |
| Amgen INC. | $22.12 | 2024 | Uplizna |
| Neurelis, INC. | $21.27 | 2025 | Valtoco |
| Scilex Pharmaceuticals INC. | $20.08 | 2025 | |
| Ucb, INC. | $15.35 | 2025 | Fintepla |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Iris Lin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.